References
- Gu¨ rler A, Boyvat A, Tu¨ rsen U¨, Clinical manifestations of Behc¸et’ disease; an analysis of 2147 patients. Yonsei Med J (1997) 38: 423–7.
- Bang D, Honma T, Saito T et al, The pathogenesis of vascular changes in erythema nodosum-like lesions of Behc¸et’s syndrome: an electron microscopic study. Hum Pathol (1987) 18: 1172–9.
- Psychos DN, Voulgari PV, Skopouli FN et al, Erythema nodosum: the underlying conditions. Clin Rheumatol (2000) 19: 212–16.
- Lehman CW, Control of chronic erythema nodosum with naproxen. Cutis (1980) 26: 66–7.
- Ubogy Z, Persellin RH, Suppression of erythema nodosum by indomethacin. Acta Derm Venereol (1982) 62: 265– 6.
- Yurdakul S, Mat C, Tuzun Y et al, A double-blind trial of colchicine in Behc¸et’s syndrome. Arthritis Rheum (2001) 44: 2686–92.
- Miyachi Y, Taniguchi S, Ozaki M, Horio T, Colchicine in the treatment of the cutaneous manifestations of Behc¸et’s disease. Br J Dermatol (1981) 104: 67–9.
- Horio T, Danno K, Okamoto H et al, Potassium iodide in erythema nodosum and other erythematous dermatoses. J Am Acad Dermatol (1983) 9: 77– 81.
- Kaneko F, Takahashi Y, Muramatsu Y, Miura Y, Immunological studies on aphthous ulcer and erythema nodosum-like eruption in Behc¸et’s disease. Br J Dermatol (1985) 113: 303–12.
- Mizushima Y, Skin hypersensitivity to streptococcal antigens in Behc¸et’s disease: a multicenter study. J Rheumatol (1989) 16: 506–11.
- Calguneri M, Ertenli I, Kiraz S et al, Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behc¸et’s disease. Dermatology (1996) 192: 125–8.
- Kaneko F, Oyama N, Nishibu A, Streptococcal infection in the pathogenesis of Behc¸et’s disease and clinical effects of minocycline on the disease symptoms. Yonsei Med J (1997) 38: 444–54.
- Keicho N, Kudoh S, Yotsumoto H, Akagawa KS, Antilymphocytic activity of erythromycin distinct from that of FK506 or cyclosporin A. J Antibiot (1993) 46: 1406–13.
- Keicho N, Kudoh S, Yotsumoto H, Akagawa KS, Erythromycin promotes monocyte to macrophage differ- entiation. J Antibiot (1994) 47: 80–9.
- Iino Y, Toriyama M, Kudo K et al, Erythromycin inhibition of lipopolysaccharide-stimulated tumor necro- sis factor-alpha production by human monocytes in vitro. Ann Otol Rhinol Laryngol (1992) 101: 16–20.
- Miyajima M, Suga M, Nakagawa M et al, Effects of erythromycin on experimental extrinsic allergic alveoli- tis. Clin Exp Allergy (1999) 29: 253–61.
- Khair OA, Devalia JL, Abdelaziz MM et al, Effect of erythromycin on Haemophilus influenzae endotoxin induced release of IL-6, IL-8 and sICAM-1 by cultured human bronchial epithelial cells. Eur Respir J (1995) 8: 1451–7.
- Aoki Y, Kao PN, Erythromycin inhibits transcriptional activation of NF-kappaB, but not NFAT, through calcineurin-independent signaling in T cells. Antimicrob Agents Chemother (1999) 43: 2678–84.
- Cervin A, The antiinflammatory effect of erythromycin and its derivatives, with special reference to nasal polyposis and chronic sinusitis. Acta Otolaryngol (2001) 121: 83–92.
- Sasaki M, Ito T, Kashima M et al, Erythromycin and clarithromycin modulation of growth factor-induced expression of heparanase mRNA on human lung cancer cells in vitro. Mediators Inflamm (2001) 10: 259–67.
- Robinson N, Singri P, Gordon KB, Safety of the new macrolide immunomodulators. Semin Cutan Med Surg (2001) 20: 242–9.
- Chin AC, Morck DW, Merrill JK et al, Anti-inflammatory benefits of tilmicosin in calves with Pasteurella haemolytica-infected lungs. Am J Vet Res (1998) 59: 765–71.
- Aoshiba K, Nagai A, Konno K, Erythromycin shortens neutrophil survival by accelerating apoptosis. Antimicrob Agents Chemother (1995) 39: 872–7.
- Anderson R, Theron AJ, Feldman C, Membrane- stabilizing, anti-inflammatory interactions of macrolides with human neutrophils. Inflammation (1996) 20: 693–705.
- Scaglione F, Rossoni G, Comparative anti-inflammatory effects of roxithromycin, azithromycin and clarithro- mycin. J Antimicrob Chemother (1998) 41 (suppl B): 47–50.